Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Nan Hee Cho  (Cho NH) 3 Articles
Diabetes, Obesity and Metabolism
Association of Protein Z with Prediabetes and Type 2 Diabetes
Yun-Ui Bae, Ji Hong You, Nan Hee Cho, Leah Eunjung Kim, Hye Min Shim, Jae-Hyung Park, Ho Chan Cho
Endocrinol Metab. 2021;36(3):637-646.   Published online June 2, 2021
  • 4,460 View
  • 140 Download
  • 5 Citations
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease. Early detection of prediabetes is important to reduce the risk of T2DM. Some cytokines are known to be associated with T2DM. Therefore, we aimed to identify cytokines as novel biomarkers of glucose dysmetabolism.
The first stage of the study included 43 subjects (13 subjects with newly diagnosed T2DM, 13 with prediabetes, and 16 with normoglycemia) for cytokine microarray analysis. Blood samples of the subjects were assessed for 310 cytokines to identify potential indicators of prediabetes. The second stage included 142 subjects (36 subjects with T2DM, 35 with prediabetes, and 71 with normoglycemia) to validate the potential cytokines associated with prediabetes.
We identified 41 cytokines that differed by 1.5-fold or more in at least one out of the three comparisons (normoglycemia vs. prediabetes, normoglycemia vs. T2DM, and prediabetes vs. T2DM) among 310 cytokines. Finally, we selected protein Z (PROZ) and validated this finding to determine its association with prediabetes. Plasma PROZ levels were found to be decreased in patients with prediabetes (1,490.32±367.19 pg/mL) and T2DM (1,583.34±465.43 pg/mL) compared to those in subjects with normoglycemia (1,864.07±450.83 pg/mL) (P<0.001). There were significantly negative correlations between PROZ and fasting plasma glucose (P=0.001) and hemoglobin A1c (P=0.010).
PROZ levels were associated with prediabetes and T2DM. We suggest that PROZ may be a promising biomarker for the early detection of prediabetes. Further large-scale studies are needed to evaluate the relationship and mechanism between PROZ and prediabetes and T2DM.


Citations to this article as recorded by  
  • On the human health benefits of microalgal phytohormones: An explorative in silico analysis
    Angelo Del Mondo, Annamaria Vinaccia, Luigi Pistelli, Christophe Brunet, Clementina Sansone
    Computational and Structural Biotechnology Journal.2023; 21: 1092.     CrossRef
  • Role of F-box WD Repeat Domain Containing 7 in Type 1 Diabetes
    Sarah W. Mohammed, Zainab M. Qassam, Ekhlass M. Taha, Nameer M. Salih
    Ibn AL-Haitham Journal For Pure and Applied Sciences.2023; 36(3): 167.     CrossRef
  • Identification of Protein Z as a Potential Novel Biomarker for the Diagnosis of Prediabetes
    Seung-Hoi Koo
    Endocrinology and Metabolism.2021; 36(3): 572.     CrossRef
  • Association of Protein Z with Prediabetes and Type 2 Diabetes (Endocrinol Metab 2021;36:637-46, Yun-Ui Bae et al.)
    Ji Hong You, Yun-Ui Bae, Ho Chan Cho
    Endocrinology and Metabolism.2021; 36(5): 1149.     CrossRef
  • Association of Protein Z with Prediabetes and Type 2 Diabetes (Endocrinol Metab 2021;36:637-46, Yun-Ui Bae et al.)
    Tiffany Pascreau, Maia Tchikviladze, Emilie Jolly, Sara Zia-Chahabi, Bertrand Lapergue, Marc Vasse
    Endocrinology and Metabolism.2021; 36(5): 1147.     CrossRef
Close layer
Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance
Eugene Han, Nan Hee Cho, Seong-Su Moon, Hochan Cho
Endocrinol Metab. 2020;35(2):480-483.   Published online June 24, 2020
  • 4,644 View
  • 113 Download
  • 3 Citations
AbstractAbstract PDFPubReader   ePub   
We investigated proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations in individuals with normoglycemia, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT). This was a pilot, cross-sectional study including 92 individuals who had not been diagnosed with or treated for diabetes. We measured PCSK9 levels in three groups of subjects; namely, normoglycemia (n=57), IFG (n=21), and IGT (n=14). Individuals with IFG and IGT showed higher PCSK9 concentrations than those in the normoglycemic group, with the highest serum PCSK9 concentrations found in individuals with IGT (55.25±15.29 ng/mL for normoglycemia, 63.47±17.78 ng/mL for IFG, 72.22±15.46 ng/mL for IGT, analysis of variance P=0.001). There were no significant differences in high- or low-density lipoprotein cholesterol among groups. Serum PCSK9 levels are increased in patients with prediabetes compared to subjects with normoglycemia.


Citations to this article as recorded by  
  • Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
    Thomas Grewal, Christa Buechler
    International Journal of Molecular Sciences.2022; 23(3): 1070.     CrossRef
  • Insight into the Evolving Role of PCSK9
    Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień
    Metabolites.2022; 12(3): 256.     CrossRef
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
    Susanne Feder, Reiner Wiest, Thomas S. Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
    Lipids in Health and Disease.2021;[Epub]     CrossRef
Close layer
Clinical Characteristics of Patients with Adrenal Insufficiency in a General Hospital
Ye Yeon Lee, Nan Hee Cho, Jong Won Lee, Nam Kyung Kim, Hye Soon Kim, Mi-Kyung Kim
Endocrinol Metab. 2017;32(1):83-89.   Published online February 28, 2017
  • 3,977 View
  • 54 Download
  • 6 Citations
AbstractAbstract PDFPubReader   

Adrenal insufficiency (AI) is a life-threatening disorder caused by the deficiency of adrenal steroid hormones. This retrospective cross-sectional study investigated the characteristics of patients with AI in Korea.


All consecutive patients with suspected AI who received care at a tertiary referral center in Korea in 2014 and underwent adrenocorticotropic hormone stimulation or insulin-tolerance testing were identified through a review of medical charts. Patients diagnosed with AI were enrolled. Their demographic, clinical, and treatment details were extracted.


Of 771 patients with suspected AI, 183 (23.7%) received a definitive diagnosis. The most common reason for testing was the presence of suspicious AI-related symptoms (30.0%), followed by a history of steroid medications (23.5%). Their mean age was 66.7 years, and females predominated (67.8%). The most common symptoms were general weakness, anorexia, arthralgia, and fever. Approximately half (53.6%) had a history of steroid use. Hydrocortisone was the most common treatment (71.6%), with most patients taking a 30 mg dose (44.2%). The most common dose frequency was twice a day (78.6%). Fourteen patients were treated for adrenal crisis (n=10, 5.5%) or an intercurrent illness (n=4, 2.2%).


AI may have been caused by steroid medication use in many of the patients included in this study. The detection of AI can be improved by careful history-taking and being alert to the possibility that a patient has used steroids.


Citations to this article as recorded by  
  • Risk of Mental Illnesses in Patients With Hypopituitarism: A Nationwide Population-Based Cohort Study
    I-Hua Wei, Chih-Chia Huang
    Psychiatry Investigation.2022; 19(6): 418.     CrossRef
  • The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
    Bradley D. Menz, Jacinta L. Johnson, Davina F. Gillard, William Chong, Michael B. Ward
    Journal of Pharmacy Practice.2021; 34(3): 386.     CrossRef
  • Clinical and biochemical factors to predict biochemical adrenal insufficiency in hospitalized patients with indeterminate cortisol levels: a retrospective study
    Worapaka Manosroi, Natapong Kosachunhanan, Pichitchai Atthakomol
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Possible adrenal insufficiency among fatigue patients in a psychosomatic medical clinic
    Sunao Matsubayashi, Nobuhiro Nakatake, Takeshi Hara
    Endocrine Journal.2020; 67(1): 53.     CrossRef
  • Encountering COVID-19 as Endocrinologists
    Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee
    Endocrinology and Metabolism.2020; 35(2): 197.     CrossRef
  • Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data
    Kamran Iqbal, Kate Halsby, Robert D Murray, Paul V Carroll, Robert Petermann
    Endocrine Connections.2019; 8(1): 20.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism